We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.45 | 3.30 | 3.60 | 3.45 | 3.45 | 3.45 | 25,672 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.9M | -2.6M | -0.0272 | -1.27 | 3.29M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/8/2020 14:14 | Guess only takes a few buys or sells to move this one | nallen1 | |
07/8/2020 13:02 | Something happening? | nmulm | |
07/8/2020 10:10 | The results last year were on Tuesday July 2nd, when I asked Anna (Walbrooke) last week about when the results will publish, she said they should be out within two weeks, so next week? What I want to know is now many of the new projects they are undertaking for customers are they managing to negotiate a royalty or milestone in addition to the fee for service. I think this is probably critical for a medium term re-rating of the shares, although I suspect many investors eyes will just be scanning the results for the word COVID, which may drive the share price in the short term. | timbo003 | |
06/8/2020 07:41 | This reminds me of the terrible spread on TILS weeks before it became the latest hot stock. Don't let a big spread put you off buying if you have done the research you have to pay the price given. | whatsthepoint | |
05/8/2020 22:14 | Anyone know when next news may be due? Just a small stake for now but might pick up more in the coming months | money4me | |
05/8/2020 19:55 | I think the market makers know that there are a lot of long term holders who have no intention of selling...😉 | woodpeckers | |
05/8/2020 15:51 | Been monitoring this for a few weeks, however, that spread is outrageous. | lako42 | |
04/8/2020 22:45 | Yanks going down the MAB route looking for an effective treatment for Covid-reckon authorities the world over looking beyond vaccines which may or may not work. But MABs could be the way forward in managing a lot of the more obstreperous infectious diseases. Something here for Fab's library maybe? hxxps://investor.lil | cumnor | |
03/8/2020 17:18 | Yes any good news and it's at least a bagger here. Still been adding bits here and there will stop at my next big purchase or a massive rise which ever comes first | fund1 | |
03/8/2020 16:56 | It's interesting that a small premium was paid for the 10k this morning, with a little bit of buying pressure this should lift off. GLA | mickluv1 | |
31/7/2020 22:33 | Our turn coming soon. I have a little bit at the side incase of anymore dips | fund1 | |
29/7/2020 18:27 | I see the 7k buy pushed it up. I can't even imagine what real positive news will do to the price when there is a scramble for the shares if 7k can push it up 3 percent. | fund1 | |
28/7/2020 13:08 | Ignoring covid. H1 report looked good with the library forecast them to start to kick in H1 2021 which is the period we are in now. Materials revenues to kick in forecast 2022 = 1st April 2021 on. YE already suggested 79% up on last year. Bio = big spending but not at Fab as its a service, and has had 8 of the top 10 biggest pharmacies companies so far as a client. The recent covid plan is different they are doing that off their own bat and will market it. Parts of that like proteins going on offer now. | superg1 | |
27/7/2020 14:28 | Yep if you want to buy, it’s worth grabbing them whilst you get the chance. You may well be able to get them cheaper if you wait but you run the risk of it getting away from you very quickly if positive news breaks and the herd chase it. As others have said picking up in dribs and drabs works best. | acuere | |
27/7/2020 13:41 | The MMs hold no stock they simply react to buys and sells on this one hence it makes big moves on small buying and selling. They already have revenue flow from their business but obviously on the Covid side, success should equate to multiples off this price, that's the theory. Not a test, not symptoms reduction, neutralisation before it takes hold, by administering covid killing antibodies to patients. | superg1 | |
27/7/2020 13:12 | Got a few more at 105p | volsung | |
27/7/2020 12:30 | Nice I would like to see the scramble for shares if good news hits will be very hard to get a decent holding then. | fund1 | |
27/7/2020 12:27 | I've done the same Fund1 | thejaba | |
27/7/2020 12:22 | Just added a few more today. Happy the more it dips for now. | fund1 | |
27/7/2020 12:18 | Yes I noticed that with the last 10k I added had to that in stages. | fund1 | |
27/7/2020 12:04 | Fund1 Any meaningful adding is tough to do. Only about 26 mill shares with 70% or so of those tied up with major holders. So not that many shares to fight over if they crack it re Covid antibodies and it starts to go a bit loopy. | superg1 | |
26/7/2020 14:16 | Could do with it dipping a bit more as I want to keep adding. | fund1 | |
26/7/2020 08:02 | Pretty much states it in the last relevant update 8th July. Antibodies sorted, antigens too which are the catalyst to multiply the covid antibodies. The Company has commenced its proof-of-concept work on the Mammalian Antibody Library Discovery Platform (the "Library") and hit its first milestone in the COVID-19 associated project, with the synthesis of the antibody library DNA. The Company has also made rapid progress on the design, expression and validation of the COVID-19 antigens and now has sufficient quantities of two variants to be used in the panning of the library for specific antibody producing cells, which is the next phase of the Library development programme. The multiple COVID-19 proteins generated are also being made available to diagnostic companies for potential commercial development. Furthermore, the Company has commenced the process for recruiting additional scientists to undertake the proof-of-concept work. | superg1 | |
26/7/2020 07:54 | So it's pretty simple gamble re Covid> FAB either will or won't be able to produce antibodies as a Covid virus killer which can be administered to those with infected with it. They have done it for various viruses, so if they can, logic suggests the large bio companies will be highly interested. The CEO did say something like Covid is an opportunity for them to showcase what they do. | superg1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions